Skip to main content
Fig. 5 | Journal of Orthopaedic Surgery and Research

Fig. 5

From: Exosomal miR-182 derived from bone marrow mesenchymal stem cells drives carfilzomib resistance of multiple myeloma cells by targeting SOX6

Fig. 5

Exosomal miR-182 secreted by BMSCs conferred the proliferation, metastasis, and carfilzomib resistance. MM-BMSCs were transfected with antagomir NC or miR-182 antagomir, respectively. A, B qRT-PCR detected the expression of miR-182 in A MM-BMSCs and B MM-BMSCs-Exos. The exosomes were obtained from BMSCs that were transfected with antagomir NC or miR-182 antagomir, and named control, Exos−control, Exos−antagomir NC, Exos−miR−182 antagomir. C CCK-8 assay was utilized to evaluate MM.1S and U266 cell proliferation. D, E Transwell assay was performed to assess cell D migration and E invasion. F CCK-8 assay was conducted to determine the half-maximal inhibitory concentration (IC50) of carfilzomib

Back to article page

Journal of Orthopaedic Surgery and Research

ISSN: 1749-799X